通过同时接种优化免疫规划:上海PCV13与轮状病毒疫苗联合接种的安全性与成本分析
本研究评估上海2岁以下婴儿同时接种13价肺炎球菌结合疫苗(PCV13)与轮状病毒疫苗的安全性和经济影响。结果显示,同时接种与单独接种的系统性不良事件发生率无统计学显著差异,部分剂次同时接种可降低成本,在直接非医疗成本和间接成本上节省尤为明显。
要点
- 同时接种PCV13与轮状病毒疫苗的系统性不良事件发生率为4.11%,与单独接种无统计学显著差异。
- 部分剂次同时接种可降低成本,1、2、3剂次联合接种总成本分别降低2.29%、2.20%、1.07%。
- 成本节省主要来自直接非医疗成本和间接成本,潜在节省超过40%。
核心结论
- 与单独接种轮状病毒疫苗和PCV13相比,同时接种优化了免疫规划的资源利用,通过减少就诊次数降低家庭成本,且安全性良好。
研究设计与样本
- 研究聚焦2岁以下婴儿,在城市和郊区诊所评估PCV13与轮状病毒疫苗同时接种的安全性,不良事件在接种当天和7天随访中监测。
- 经济评估从社会视角进行,计算直接医疗、非医疗和间接成本,按每剂次和每名全程免疫儿童计算成本,采用成本最小化分析(CMA)和预算影响分析(BIA),并进行敏感性分析。
主要发现
- 系统性不良事件发生率:单独接种PCV13为4.82%,单独接种轮状病毒疫苗为4.35%,同时接种为4.11%,三种接种模式间无统计学显著差异。
- 与当前分开接种方案相比,同时接种1、2、3剂次的总成本分别降低2.29%、2.20%、1.07%。
- 成本节省主要来自直接非医疗成本和间接成本,潜在节省超过40%。
临床怎么用
- 原文结论认为,同时接种策略对于提升人口密集城市地区免疫规划的效率和可持续性尤其有价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The implementation of concurrent vaccination strategies presents a promising approach to simplify complex immunization schedules while maintaining vaccine safety and efficacy. This study evaluates both the safety profile and economic impact of co-administering 13-valent pneumococcal conjugate vaccine (PCV13) and rotavirus vaccines in Shanghai, China. METHODS: The study focuses on infants under 2 years old. The safety of concurrent PCV13 and rotavirus vaccination was assessed across urban and suburban clinics, with adverse events monitored on the day of vaccination and via 7-day follow-up. The economic evaluation, conducted from a societal perspective, accounted for direct medical, non-medical, and indirect costs. Costs were calculated per dose and per fully immunized child. Economic analyses utilized cost-minimization analysis (CMA) and budgetary impact analysis (BIA), with sensitivity analyses to ensure robustness. FINDINGS: The incidence of systemic adverse effects was 4.82 % for PCV13 alone, 4.35 % for rotavirus vaccine alone, and 4.11 % for simultaneous vaccination, with no statistically significant differences between the three patterns of vaccination. Partial-dose concurrent vaccination is cost-effective, with total costs reduced by 2.29 %, 2.20 %, and 1.07 % for co-administering 1, 2, and 3 doses, respectively, compared to the current separate administration schedule. Cost savings are predominantly achieved in direct non-medical costs and indirect costs, with potential savings exceeding 40 %. INTERPRETATION: Compared to separate administration of RV and PCV13, concurrent administration optimizes resource utilization in immunization programs, reduces costs to families by reducing clinic visits, and has a favorable safety profile. This strategy is especially valuable for enhancing the efficiency and sustainability of immunization programs in densely populated urban settings.
引用
- Tian J, Wang X, Gu L, et al. Optimizing immunization through concurrent vaccination: a safety and cost analysis of PCV13 and rotavirus vaccines co-administration in Shanghai. Vaccine. 2025. PMID: 41172934. doi:10.1016/j.vaccine.2025.127880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。